JULY 2023LIFE SCIENCES REVIEW5Specialized Services: A New Paradigm in TherapeuticsBrian D. Fry,Senior Director, Cell Therapy CDMO, Charles River LaboratoriesIN MY OPINION08LAST WORD30CXO INSIGHTSThe Role of Patient Reported Outcomes to Support Reimbursement and Market Access in Major European Countries and the USLothar Tremmel, Vice President, QCSR, CSL Behring26Expanding the Promise of Immunotherapy Beyond the Oncology RealmJames Riddle, MCSE, CIP, CPIA, CRQM, Vice President, Research Services & Strategic Consulting, Advarra28Analytical Considerations for Combination ProductsJennifer L. Riter, Sr. Director, Business and Technical Operations, Services and Solutions, West Pharmaceutical Services, Inc.20Purpose-Led LeadershipLiv Wilson, Head of Douglas Learning Academy, Douglas Pharmaceuticals22Improving Minimal ResidualDisease Detection Using NGSSteven Henck, PhD, Vice President of R&D, Integrated DNA Technologies24Accelerating drug development of novel targeted therapies through histology-agnostic oncology clinical trialsHua Gong, M.D., Ph.D., SVP, Global Head of Translational Medicine and Clinical Biomarker, Zai Lab18The Tipping Point for Scalable Manufacturing Processes to Pivot Gene TherapiesDr. Linda Randall, AVP, Biologics Development, Manufacturing & Control, Pharmaron
< Page 4 | Page 6 >